| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Guy A Higgins, Edward M Sellers, Paul J Fletche. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. Trends in pharmacological sciences. vol 34. issue 10. 2014-02-14. PMID:24041919. |
the recent us food and drug administration (fda) approval of the serotonin (5-hydroxytryptamine, 5-ht) 5-ht2c receptor agonist lorcaserin for the treatment of obesity represents a new therapeutic drug class available to the clinic. |
2014-02-14 |
2023-08-12 |
Not clear |
| Helen D Berlie, Kathryn M Hurre. Evaluation of lorcaserin for the treatment of obesity. Expert opinion on drug metabolism & toxicology. vol 9. issue 8. 2014-02-07. PMID:23802690. |
lorcaserin , a novel serotonin 2c receptor antagonist, was recently approved as an adjunct to lifestyle modification for long-term weight loss and maintenance. |
2014-02-07 |
2023-08-12 |
Not clear |
| Sheridan M Ho. Lorcaserin: a review of its use in chronic weight management. Drugs. vol 73. issue 5. 2014-02-03. PMID:23529825. |
oral lorcaserin (belviq(®)), a selective serotonin 5-ht2c receptor agonist, is indicated in the us as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. |
2014-02-03 |
2023-08-12 |
Not clear |
| Stefanie C Nigro, Darren Luon, William L Bake. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Current medical research and opinion. vol 29. issue 7. 2014-01-08. PMID:23574263. |
lorcaserin: a novel serotonin 2c agonist for the treatment of obesity. |
2014-01-08 |
2023-08-12 |
Not clear |
| Stefanie C Nigro, Darren Luon, William L Bake. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Current medical research and opinion. vol 29. issue 7. 2014-01-08. PMID:23574263. |
the objective of this paper was to review the place of lorcaserin, a novel serotonin 2c agonist, which was fda approved in july 2012. |
2014-01-08 |
2023-08-12 |
Not clear |
| Rick Hess, L Brian Cros. The safety and efficacy of lorcaserin in the management of obesity. Postgraduate medicine. vol 125. issue 6. 2014-01-06. PMID:24200762. |
lorcaserin is a centrally acting, selective serotonin c (5-ht2c) receptor full agonist that is associated with increased satiety and decreased food consumption in patients. |
2014-01-06 |
2023-08-12 |
Not clear |
| Rick Hess, L Brian Cros. The safety and efficacy of lorcaserin in the management of obesity. Postgraduate medicine. vol 125. issue 6. 2014-01-06. PMID:24200762. |
the selectivity of lorcaserin for 5-ht2c receptors should reduce patient risk for the serious adverse complications that are associated with nonselective 5-ht agonist therapies, such as cardiac valvulopathy and pulmonary hypertension. |
2014-01-06 |
2023-08-12 |
Not clear |
| Shinichi Ogino, Yukinori Nagakura, Mina Tsukamoto, Tomonari Watabiki, Tohru Ozawa, Tomoya Oe, Yasuaki Shimizu, Hiroyuki It. Systemic administration of 5-HT(2C) receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model. Pharmacology, biochemistry, and behavior. vol 108. 2014-01-02. PMID:23603031. |
three 5-ht(2c) receptor agonists (lorcaserin, vabicaserin and ym348) that have been suggested to be useful in the treatment of several central nervous system diseases, including obesity and schizophrenia, were used. |
2014-01-02 |
2023-08-12 |
rat |
| Shinichi Ogino, Yukinori Nagakura, Mina Tsukamoto, Tomonari Watabiki, Tohru Ozawa, Tomoya Oe, Yasuaki Shimizu, Hiroyuki It. Systemic administration of 5-HT(2C) receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model. Pharmacology, biochemistry, and behavior. vol 108. 2014-01-02. PMID:23603031. |
the effect of lorcaserin was reversed by the pretreatment with sb242084, a 5-ht(2c) receptor antagonist. |
2014-01-02 |
2023-08-12 |
rat |
| Ashley Gustafson, Camille King, Jose A Re. Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity. P & T : a peer-reviewed journal for formulary management. vol 38. issue 9. 2013-11-25. PMID:24273398. |
lorcaserin (belviq): a selective serotonin 5-ht2c agonist in the treatment of obesity. |
2013-11-25 |
2023-08-12 |
Not clear |
| Corey R Hopkin. ACS chemical neuroscience molecule spotlight on Lorcaserin. ACS chemical neuroscience. vol 1. issue 11. 2013-08-09. PMID:22778808. |
lorcaserin (apd-356) is the first in a new class of selective serotonin 5-hydroxytryptamine(2c) (5-ht(2c)) receptor agonists. |
2013-08-09 |
2023-08-12 |
Not clear |
| James R Taylor, Eric Dietrich, Jason Powel. Lorcaserin for weight management. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 6. 2013-06-24. PMID:23788837. |
lorcaserin, a novel antiobesity agent, affects central serotonin subtype 2a receptors, resulting in decreased food intake and increased satiety. |
2013-06-24 |
2023-08-12 |
Not clear |
| Sharon Rosenzweig-Lipson, Thomas A Comery, Karen L Marquis, Jonathan Gross, John Dunlo. 5-HT(2C) agonists as therapeutics for the treatment of schizophrenia. Handbook of experimental pharmacology. issue 213. 2013-01-10. PMID:23027415. |
while several 5-ht(2c) agonists have demonstrated clinical efficacy in obesity (lorcaserin, prx-000933), the focus of this review is on the therapeutic potential of 5-ht(2c) agonists in schizophrenia. |
2013-01-10 |
2023-08-12 |
human |
| Abu J M Sadeque, Khawja A Usmani, Safet Palamar, Matthew A Cerny, Weichao G Che. Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin. Drug metabolism and disposition: the biological fate of chemicals. vol 40. issue 4. 2012-08-03. PMID:22259019. |
lorcaserin, a selective serotonin 5-ht(2c) receptor agonist, is a weight management agent in clinical development. |
2012-08-03 |
2023-08-12 |
human |
| Khawja A Usmani, Weichao G Chen, Abu J M Sadequ. Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug metabolism and disposition: the biological fate of chemicals. vol 40. issue 4. 2012-08-03. PMID:22266842. |
identification of human cytochrome p450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2c agonist. |
2012-08-03 |
2023-08-12 |
human |
| Khawja A Usmani, Weichao G Chen, Abu J M Sadequ. Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug metabolism and disposition: the biological fate of chemicals. vol 40. issue 4. 2012-08-03. PMID:22266842. |
lorcaserin, a selective serotonin 5-hydroxytryptamine 2c receptor agonist, is being developed for weight management. |
2012-08-03 |
2023-08-12 |
human |
| Guy A Higgins, Leo B Silenieks, Anne Rossmann, Zoe Rizos, Kevin Noble, Ashlie D Soko, Paul J Fletche. The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 37. issue 5. 2012-07-20. PMID:22189292. |
lorcaserin ((1r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine hcl) is a selective 5-ht(2c) receptor agonist with clinical efficacy in phase-iii obesity trials. |
2012-07-20 |
2023-08-12 |
rat |
| Guy A Higgins, Leo B Silenieks, Anne Rossmann, Zoe Rizos, Kevin Noble, Ashlie D Soko, Paul J Fletche. The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 37. issue 5. 2012-07-20. PMID:22189292. |
importantly, these results indicate that lorcaserin, and likely other selective 5-ht(2c) receptor agonists, similarly affect both food- and nicotine-motivated behaviors, and nicotine-induced impulsivity. |
2012-07-20 |
2023-08-12 |
rat |
| Guy A Higgins, Leo B Silenieks, Anne Rossmann, Zoe Rizos, Kevin Noble, Ashlie D Soko, Paul J Fletche. The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 37. issue 5. 2012-07-20. PMID:22189292. |
collectively, these findings highlight a therapeutic potential for 5-ht(2c) agonists such as lorcaserin beyond obesity into addictive behaviors, such as nicotine dependence. |
2012-07-20 |
2023-08-12 |
rat |
| Jason C G Halford, Emma J Boyland, Clare L Lawton, John E Blundell, Joanne A Harrol. Serotonergic anti-obesity agents: past experience and future prospects. Drugs. vol 71. issue 17. 2012-07-16. PMID:22085383. |
the serotonin 5-ht(2c)-receptor selective agonist lorcaserin, a drug specifically developed to target satiety without producing the side effect profiles of its predecessors, has been shown to significantly reduce energy intake and body weight. |
2012-07-16 |
2023-08-12 |
Not clear |